Core Viewpoint - China Biotechnology Services (08037.HK) reported a significant improvement in financial performance for the six months ending June 30, 2025, with a revenue increase of 19.8% year-on-year, indicating effective cost control measures and compensation income from insurance claims [1] Financial Performance - Revenue reached HKD 38.872 million, up 19.8% compared to the previous year [1] - Gross profit was HKD 2.542 million, a recovery from a gross loss of HKD 3.107 million in the same period last year [1] - The loss attributable to owners of the company was HKD 32.006 million, a significant reduction of 60.0% from HKD 79.917 million in the prior year [1] - Basic loss per share was HKD 0.033 [1] Operational Improvements - The improvement in operational performance was primarily due to successful implementation of cost control measures, leading to an increase in gross margin and a reduction in administrative expenses [1] - The company received approximately HKD 13.7 million in compensation income related to damages from heavy rainfall affecting construction sites in Hainan during 2024 [1]
中国生物科技服务(08037.HK)：中期净亏损3200.6万港元